(NASDAQ: VBIV) Vbi Vaccines's forecast annual revenue growth rate of 88.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Vbi Vaccines's revenue in 2024 is $8,682,000.On average, 1 Wall Street analysts forecast VBIV's revenue for 2024 to be $411,699,342, with the lowest VBIV revenue forecast at $411,699,342, and the highest VBIV revenue forecast at $411,699,342. On average, 1 Wall Street analysts forecast VBIV's revenue for 2025 to be $970,109,223, with the lowest VBIV revenue forecast at $970,109,223, and the highest VBIV revenue forecast at $970,109,223.
In 2026, VBIV is forecast to generate $1,672,955,061 in revenue, with the lowest revenue forecast at $1,672,955,061 and the highest revenue forecast at $1,672,955,061.